Discovery and Origin of BPC-157
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide consisting of fifteen amino acids with the sequence GEPPPGKPADDAGLV and a molecular weight of 1419 daltons. The compound derives its name from research conducted on a protein isolated from human gastric juice, where a larger body protection compound was first identified. BPC-157 represents a partial sequence of this parent protein, synthesized for use in laboratory investigations.
The discovery of BPC-157 has been documented in published literature dating to the early 1990s, when researchers in Croatia began characterizing gastric juice-derived peptides and examining their properties in preclinical models. Since that time, BPC-157 has become one of the most extensively studied synthetic peptides in preclinical tissue research, with dozens of published studies examining its interactions with cellular repair pathways.
Unlike many peptides derived from endogenous hormones or neurotransmitters, BPC-157 is notable for being derived from a gastrointestinal protein rather than a neuroendocrine source. This origin has been observed to distinguish it from other research peptides in the literature and has prompted investigations into gastric-derived signaling molecules as a broader class of bioactive compounds.
Solid-Phase Peptide Synthesis of BPC-157
BPC-157 is manufactured through solid-phase peptide synthesis (SPPS), the standard chemical methodology for producing research-grade peptides. In this process, amino acids are sequentially coupled to a growing chain anchored to a solid resin support. Each coupling cycle involves deprotection of the terminal amino group, activation of the incoming amino acid, and formation of a new peptide bond.
The fifteen-amino-acid sequence of BPC-157 is assembled from C-terminus to N-terminus, with protective groups preventing unwanted side reactions during synthesis. Following chain assembly, the completed peptide is cleaved from the resin, deprotected, and purified using reversed-phase high-performance liquid chromatography (RP-HPLC). Mass spectrometry is employed to confirm molecular identity.
Research-grade BPC-157, such as the compound available in the Hot Peps catalog, is supplied as a lyophilized powder at a purity of 99% or greater. This high purity standard has been documented as important for ensuring reproducibility in preclinical investigations where trace contaminants could confound experimental outcomes.
Preclinical Tendon and Tissue Research
The majority of published research on BPC-157 has been conducted in preclinical models examining tissue repair pathways. A 2025 systematic review published in the Orthopaedic Journal of Sports Medicine by Vasireddi and colleagues analyzed thirty-six studies spanning from 1993 to 2024. The review reported that BPC-157 enhanced growth hormone receptor expression and multiple pathways involved in cell growth and angiogenesis across the examined preclinical models.
Research published in the Journal of Applied Physiology by Chang and colleagues in 2011 demonstrated that BPC-157 accelerated the outgrowth of tendon explants and increased cell survival under oxidative stress conditions in rat Achilles tendon fibroblast cultures. These observations were documented in controlled in vitro experiments examining tendon cell behavior in the presence and absence of the peptide.
A study published in the Journal of Orthopaedic Research by Staresinic and colleagues in 2003 examined transected rat Achilles tendons. The investigators observed improved biomechanical outcomes, functional indices, and collagen formation in groups treated with BPC-157 compared to controls. These findings have been cited extensively in subsequent literature reviews as foundational preclinical observations.
Additional research published in Molecules by Chang and colleagues in 2014 documented that BPC-157 dose- and time-dependently increased growth hormone receptor expression in tendon fibroblasts at both mRNA and protein levels. This observation has been noted as consistent with the compound's proposed involvement in tissue remodeling signaling cascades.
Detailed research summaries for BPC-157, including full citation information, are available on the BPC-157 research page.
Proposed Mechanism of Action
Research has suggested that BPC-157 may influence several molecular signaling pathways relevant to tissue biology. Published studies have documented proposed interactions with nitric oxide (NO) pathways, which are involved in vasodilation, angiogenesis, and inflammatory signaling. The NO system has been observed to play roles in multiple tissue repair processes, and BPC-157's proposed modulation of this system has been a recurring theme in the literature.
FAK-paxillin signaling, a pathway involved in cellular adhesion, migration, and mechanotransduction, has also been documented as a potential target of BPC-157 activity. Focal adhesion kinase (FAK) and its associated protein paxillin are components of the molecular machinery that cells use to attach to extracellular matrix substrates and to transduce mechanical signals into biochemical responses. Research has suggested that BPC-157 may influence this pathway in the context of cell migration during tissue remodeling.
Growth factor expression, including vascular endothelial growth factor (VEGF) and growth hormone receptor upregulation, has been documented in multiple published studies examining BPC-157 in preclinical models. These observations have been interpreted as consistent with a compound that may interact with multiple nodes in tissue repair signaling networks.
It is important to note that the proposed mechanisms described above are derived from preclinical research and have not been confirmed through controlled clinical trials in human subjects. The mechanistic understanding of BPC-157 remains an active area of scientific investigation.
Current Research Status
As of early 2026, BPC-157 remains a preclinical research compound. It has not received regulatory approval for any therapeutic indication in any jurisdiction. The published literature on BPC-157 consists primarily of in vitro cell culture studies and in vivo animal model experiments, with the systematic review by Vasireddi et al. (2025) representing the most comprehensive analysis of the accumulated preclinical data.
BPC-157 is available as part of the Recovery Stack kit alongside GHK-Cu, a combination organized around tissue and regeneration pathway research. Individual vials are also available through the singles catalog for researchers building custom experimental protocols.
The continued publication of new preclinical studies examining BPC-157 reflects ongoing scientific interest in gastric-derived peptides and their interactions with tissue repair signaling pathways. Researchers are encouraged to consult the primary literature and the Hot Peps research hub for the most current published findings.
Research Compliance Disclaimer
All information presented in this article reflects outcomes and observations reported in published research studies. BPC-157 is sold strictly for in vitro research, laboratory use, and scientific investigation only. It is not intended for human consumption, veterinary use, or any diagnostic or therapeutic application. No information in this article constitutes medical advice or therapeutic guidance.